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The tumor is a hostile microenvironment for T lymphocytes. Indeed, irregular blood flow,
and endothelial cell (EC) anergy that characterize most solid tumors hamper leukocyte
adhesion, extravasation, and infiltration. In addition, hypoxia and reprograming of energy
metabolism within cancer cells transform the tumor mass in a harsh environment that
limits survival and effector functions of T cells, regardless of being induced in vivo by vac-
cination or adoptively transferred. In this review, we will summarize on recent advances
in our understanding of the characteristics of tumor-associated neo-angiogenic vessels as
well as of the tumor metabolism that may impact on T cell trafficking and fitness of tumor
infiltrating lymphocytes. In particular, we will focus on how advances in knowledge of the
characteristics of tumor ECs have enabled identifying strategies to normalize the tumor-
vasculature and/or overcome EC anergy, thus increasing leukocyte-vessel wall interactions
and lymphocyte infiltration in tumors. We will also focus on drugs acting on cells and
their released molecules to transiently render the tumor microenvironment more suitable
for tumor infiltrating T lymphocytes, thus increasing the therapeutic effectiveness of both
active and adoptive immunotherapies.
Keywords: cytotoxic T lymphocyte, vaccine, adoptive T cell therapy, pH, redox, proton pump inhibitor, NGR-TNF,
combination therapy
INTRODUCTION
Active and adoptive cancer immunotherapies have breached the
wall between bench and bedside at last, and have just entered a
new golden age. This is the result of several concomitant tech-
nological advancements and breakthrough discoveries. On the
one hand, powerful technical tools (e.g., tetramers and live imag-
ing) have been made available to more deeply investigate the
interactions between the growing tumor and the host, and espe-
cially the immune system. Thus, sophisticated genetically engi-
neered animal models have allowed building new theories on the
process of cancer immune surveillance (1). Furthermore, high-
throughput technologies are making possible investigating the
tumor microenvironment as a whole (2), and genomic landscap-
ing, proteomic profiling, and more recently metabolomics and
algorithms applied to cancer histochemistry (3–8) are drawing
an entirely new picture of the tumor mass. On the other hand,
strong efforts from hundreds of laboratories around the word in
the last 20 years have defined tumor-associated antigens (TAAs)
and adjuvants to such an high degree of knowledge [e.g.,(9)] that
active immunotherapy has eventually reached the bedside with
the first FDA approved cancer vaccine for metastatic prostate can-
cer patients (10). Even more importantly, clinical grade in vitro
expanded tumor infiltrating lymphocytes (TILs) and genetically
engineered T cells have demonstrated the full potential of adoptive
immunotherapy (11, 12).
Yet, several hurdles still need to be overcome (Figure 1) to
extend such treatments to the majority of cancer patients. Firstly,
the tumor mass is characterized by abnormal tumor vessels and
interstitium that limit leukocyte adhesion, extravasation, and infil-
tration (13), and favors hypoxia and reprograming of energy
metabolism within cancer cells (14). Metabolic alterations within
the tumor mass also limit T cell functions, and the tumor microen-
vironment eventually becomes a site of immune privilege where
several cancer cell intrinsic and extrinsic mechanisms suppress the
tumor-specific T cell response (15).
Here, we will summarize on recent advances in our under-
standing of the characteristics of tumor-associated neo-angiogenic
vessels as well as of the tumor metabolism that may impact on
T cell trafficking and fitness of TILs. We will also report on
drugs acting on cells and their released molecules to transiently
render the tumor microenvironment more suitable for tumor
TILs (Figure 1), thus increasing T cell trafficking into tumors
and the therapeutic effectiveness of both active and adoptive
immunotherapies.
T CELL ADHESION TO THE ENDOTHELIUM, EXTRAVASATION,
AND INFILTRATION WITHIN INFLAMED TISSUES
Once a T cell has been activated in secondary lymphoid organs,
it reaches the blood flow and navigates within vessels to the site
of extravasation, which usually coincides with a site of inflamma-
tion. Activated T cells prefer to exit the blood stream at the level
of post-capillary venules, where the hemodynamic shear stress is
lower than in arteries and capillaries and the endothelium is more
prone to extravasation. Activated T cells travel more efficiently
than naïve T cells to inflamed tissues because they upregulate adhe-
sion molecules and chemoattractant receptors for inflammation
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FIGURE 1 | Strategies that favor lymphocyte trafficking into tumors
and fitness ofTILs. The cartoon highlights abnormalities of
tumor-associated vessels and alterations of the metabolism within the
tumor microenvironment that limit lymphocyte trafficking into tumor and
TIL anti-tumor activities. Strategies to overcome such hurdles are also
indicated.
induced ligands. Transendothelial migration involves specific
adhesive interactions between T cells and endothelial cells (ECs)
that guide the lymphocytes from the vascular compartment to
the extravascular tissue. We refer the interested reader to excel-
lent reviews on this topic (16–20). In brief, T cells undergo four
distinct adhesion steps during their migration through blood
vessels. These include tethering, rolling, activation, and arrest.
Tethering and rolling of leukocytes are mediated by interactions
between selectins and specific carbohydrate moieties bound to
a protein backbone (21), which allow rapid engagement with
high tensile strength. The selectins are a family of three C-type
lectins expressed by bone marrow-derived cells and ECs. l-selectin
(CD62L) is expressed by all myeloid cells, naïve T cells, and
some activated and memory cells. P-selectin (CD62P) is found
in secretory granules of platelets and ECs and is expressed on the
cell surface after activation by inflammatory stimuli. E-selectin
(CD62E) is expressed by acutely inflamed ECs in most organs
and by non-inflamed skin microvessels. Thus, P-selectin glyco-
protein ligand 1 (PSGL-1) and CD43 on activated T cells engage
CD62P and CD62E on activated ECs, respectively. Rolling T cells
receive signals from chemokines on ECs, which induce modula-
tion of integrins to acquire high avidity for their ligands. Integrins
may participate to the rolling phase but are essential for the firm
adhesion of leukocytes. In particular, activated T cells depend
on lymphocyte function-associated antigen 1 (LFA-1), very late
antigen-4 (VLA-4;α4β1), andα4β7 for their interactions with acti-
vated ECs that express intracellular adhesion molecule 1 (ICAM-
1), intracellular adhesion molecule 2 (ICAM-2), VCAM-1, and
mucosal addressin-cell adhesion molecule type 1 (MAdCAM-1),
respectively (22).
Quiescent ECs poorly interact with circulating leukocytes.
Autacoid mediators released by mast cells and other cells of
the innate immunity, upon stimulation by inflammatory signals
(e.g., infection and tissue damage), cause rapid enhancement of
venular permeability, translocation of integrins, and chemokines
from intracellular stores to the cell surface and formation of
a provisional matrix (23), all processes that favor T cell-EC
interactions.
A very different scenario may characterize T cell-EC interac-
tions in tumor-associated vessels.
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TUMOR-ASSOCIATED MODIFICATIONS OF THE
ENDOTHELIUM HAMPER T CELL ADHESION,
EXTRAVASATION, AND TUMOR INFILTRATION
While acute inflammation is an efficacious means by which the
organism repairs a tissue that has been damaged by a physi-
cal insult or infection, chronic inflammation has emerged has
indispensable requisite for chronic diseases including cancer (24).
Indeed, tumor-promoting inflammation has been recently recog-
nized has as an enabling characteristic that allows cancer cells to
acquire multiple hallmark capabilities including sustaining prolif-
erative signaling, resisting cell death, avoiding immune destruc-
tion, activating invasion, and metastasis and inducing angio-
genesis (25). Virtually any neoplastic lesion contains immune
inflammatory cells although with variable densities (26). Yet,
gene expression profiling of the total cellular composition of
tumors has evidenced at least two subsets of tumors. The first
“inflamed” subset is characterized by transcripts encoding innate
immune cell molecules, chemokines that can contribute to effec-
tor T cell recruitment, various T lineage-specific markers, and,
paradoxically, immune inhibitory mechanisms. Conversely, the
“not-inflamed” phenotype is distinguished for high expression
of angiogenesis-associated factors as well as macrophages and
fibroblasts (2). Thus, it has been hypothesized that TILs effectively
extravasate in inflamed tumors but are inhibited by immuno-
suppressive mechanisms, including indoleamine-2,3-dioxygenase
(IDO), programed cell death 1 ligand 1 (PD-L1), and forkhead box
P3 (FoxP3)+ regulatory T cells (Tregs), whereas, T cell migration
is defective in not-inflamed tumors (2).
More in general, vessels are irregularly distributed within the
tumor mass that, when reaches 1–2 mm in diameter, presents
a patchy distribution of less-perfused and hypoxic areas (27).
Hypoxia is one of the strongest stimulators of angiogenesis, largely
through the expression of hypoxia inducible transcription factors
[HIFs; (28)]. Tumor vessels that sprout from existing ones are dis-
organized, tortuous, dilated, saccular, and leaker then the normal
ones. Also the composition of the vessel is abnormal, and ECs may
acquire aberrant morphology, pericytes may be absent or loosely
attached, and the vessel may lack basement membrane or have it
unusually thick (13, 29). In addition, tumor cells may mimic ECs
and generate vascular conduits, which however, are even more
abnormal (30). All together, these vascular abnormalities render
tumor vessels leaker then normal ones, may increase the inter-
stitial pressure, cause heterogeneous permeability, and promote
irregular blood flow, therefore making leukocyte trafficking within
the tumor mass difficult. Interstitial pressure is also increased by
the extrinsic compression of tumor vessels by proliferating cancer
cells. In addition, angiogenic factors such as vascular EC growth
factors (VEGFs) and fibroblast growth factors (FGFs) cause down-
regulation of ICAM-1/2, VCAM-1, and CD34 on ECs, a phenom-
enon defined as “EC anergy” (31–33). Thus, the few effector T
cells that circulate in tumor vessels, regardless of being induced
in vivo by vaccination or adoptively transferred (34, 35), can hardly
interact with ECs and begin their migration through blood vessels
(Figure 2A). In line with this view, gene expression profiling and
in situ immunohistochemical staining of large cohorts of cancer
patients have shown that more aggressive tumors are characterized
by peritumoral immune infiltrates (36), whereas a strong in situ
accumulation of T cells both in the center of the tumor and the
invading margin correlates with a favorable prognosis regardless
of the local extent of the tumor and of metastasis (37).
WAYS TO FAVOR T CELL ADHESION TO TUMOR-ASSOCIATED
ENDOTHELIAL CELLS, EXTRAVASATION, AND TUMOR
INFILTRATION
Crossing the abnormal tumor vessel barrier and interstitium is
one major hurdle for tumor-specific T cells that have reached
the tumor mass (Figure 1). Few years ago, we proposed that
delivery of vasoactive inflammatory cytokines like tumor necro-
sis factor α (TNF) to neo-angiogenic vessels might represent a
good strategy to induce selective activation of ECs in tumor tis-
sues, thereby enhancing T cell extravasation and tumor infiltration
(38). TNF is produced in the tumor microenvironment mainly by
macrophages, but also by smooth muscle cells, ECs and tumor
cells (39), and it affects primarily the tumor-associated vascula-
ture (40). Indeed, most tumor cells and vessels of normal tissues
are resistant to TNF (41). Depending on the amount of TNF that
reaches the tumor mass, its effects range from EC activation, to
increased vessel permeability, EC damage, and massive hemor-
rhagic necrosis (42). The in vivo effects of TNF have been well
characterized both in pre-clinical models and in humans under-
going isolated limb perfusion, a regional cancer therapy used to
deliver high doses of a drug into the bloodstream of a limb avoid-
ing severe systemic side effects (42). An alternative strategy to
avoid TNF-induced systemic toxicity is indeed to selectively target
minute amounts of the cytokine to the tumor vessels. Selective
delivery of TNF to tumor vessels has been achieved by fusing this
cytokine with a tumor-vasculature-homing peptide that contains
the Cys-Asn-Gly-Arg-Cys (NGR) sequence, a ligand of a CD13 iso-
form expressed by neo-angiogenic vessels (43, 44). The new moiety
called NGR-TNF was shown to transiently enhance tumor vessel
permeability (45), thus increasing the penetration of chemother-
apy agents in murine models of lymphoma, melanoma, and spon-
taneous prostate cancer without TNF-related systemic toxicity (46,
47). NGR-TNF is currently under clinical investigation in various
clinical studies in cancer patients (48).
In accordance with our original hypothesis (38), we have
recently shown that extremely low doses of NGR-TNF (5 ng/Kg)
are sufficient to induce the up-regulation of VCAM-1 and ICAM-
2 on the endothelial lining of tumor vessels as well as the release,
in the tumor microenvironment, of chemokines that favor T-
cell trafficking (Figure 2B). Rapid and transient modification
of the tumor microenvironment can enhance the infiltration of
either fully activated endogenous or adoptively transferred T cells
in transplantable melanoma and autochthonous prostate can-
cer (49). Additionally, we have demonstrated that NGR-TNF can
increase the therapeutic efficacy of tumor vaccines and adoptive
immunotherapy with no evidence of toxic reactions (49). The
effects of NGR-TNF on tumor infiltration by leukocytes go beyond
the transient activation of tumor-associated ECs (50). Indeed,
NGR-TNF transiently modifies the endothelial barrier function by
loosening VE-cadherin dependent adherence junctions (51), thus
favoring T cell extravasation (Figure 2B). It can also transiently
reduce hypoxic areas of the tumor (52) and favor TIL proliferation
and survival (50).
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FIGURE 2 | Strategies to increaseT cell infiltration into tumors. (A)
Increased interstitial pressure, heterogeneous permeability and irregular
blood flow, together with reduced expression of adhesion molecules on
ECs, limit lymphocyte penetration in tumors. (B) NGR-TNF, which
selectively binds CD13 expressed in ECs of neo-angiogenic vessels and
favors the interaction of TNF with TNF receptors (TNF-Rs), alters tumor
vessel permeability by loosening VE-cadherin dependent adherence
junctions, induces up-regulation of adhesion molecules in ECs, and elicits
the release of pro-inflammatory cytokines and chemokines, thereby
favoring the recruitment and extravasation of T lymphocytes. (C)
Anti-VEGF and anti-VEGF-R antibodies both transiently normalize the
tumor-vasculature and overcome EC anergy, thus favoring T cell trafficking
within tumors. (D) Also immunization against VEGF-R2 or the adoptive
transfer of autologous T cells genetically engineered to express chimeric
antigen receptor targeted against VEGF-R2 (VEGFR-CAR) favor tumor
infiltration by T cells, although the mechanism has not yet been clarified. It
has been proposed that VEGF-R-specific T cells kill both ECs and MDSCs
and Tregs (not shown) that express VEGF-R.
A similar compound, consisting of TNF fused to another
tumor-vasculature-homing peptide (RGR) has been recently
shown to stabilize tumor vessels and to enhance active
immunotherapy in experimental pancreatic neuroendocrine
tumors (52). Notably, a recent phase II study of NGR-TNF
(0.8µg/m2) in combination with doxorubicin in relapsed ovar-
ian cancer patients showed that patients with baseline periph-
eral blood lymphocyte count higher than the first quartile had
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improved progression-free survival and overall survival (53),
therefore suggesting that a similar effect may occur in humans.
Other strategies have been pursed to target TNF to the tumor.
As an example, TNF has been fused with the single chain Fv Ab L19,
which is specific for the extradomain B of fibronectin expressed
by the tumor neovasculature (54). However, the location of the
target molecules in tumor vessels and their level of expression are
different from that of CD13, and additional studies are necessary
to investigate whether this compound acts in synergy with active
or adoptive immunotherapy.
Leukocyte infiltration in tumors can also be favored by the use
of classic anti-angiogenic drugs. VEGF is the focus of most of
these approaches (55). The importance of VEGF-mediated mech-
anisms in cancer is underlined by clinical data showing that the
expression of VEGF in tumor tissue is negatively correlated with
the presence of TILs. This was reported to be one of the strongest
prognostic factors in ovarian carcinoma (56). In addition, VEGF
negatively regulates functional maturation of and antigen pre-
sentation by dendritic cells (DCs), favors the accrual and activity
of cell populations with immunosuppressive functions including
myeloid derived suppressor cells [MDSCs; (57)] and regulatory T
cells [Tregs; (58)], and induces T cell apoptosis, therefore con-
tributing to the immunosuppressive tumor microenvironment
(59). Over the last decades several therapeutic approaches have
been proposed to counteract VEGF and neoangiogenesis, such
as anti-VEGF antibodies and tyrosine kinase inhibitors of mul-
tiple pro-angiogenic growth factor receptors (13). Inhibition of
VEGF interaction with its receptors has been also reported to be
at the basis of vessel “normalization” (29). Anti-angiogenic drugs
transiently normalize the tumor-vasculature, pruning away imma-
ture and leaky vessels and remodeling the remaining vasculature.
As a result, the enhanced oncotic pressure gradient together with
decreased interstitial fluid pressure and hydrostatic pressure gra-
dient facilitate delivery of oxygen, nutrients, and also chemother-
apeutic agents into the tumor microenvironment (13). Some of
these strategies can also overcome EC anergy and promote leuko-
cyte infiltration in tumors [Figure 2C; (60–62)]. In addition, it has
been reported that lower-dose of anti-VEGF (DC101; 10 mg/Kg),
when compared with the standard high dose (40 mg/Kg), normal-
izes the tumor-vasculature, favors extravasation of T cells, reduces
the fraction of MDSCs, and polarizes macrophages toward an
M1 phenotype within the tumor mass (63). Thus, anti-angiogenic
drugs and TNF targeting are conceptually different approaches, as
the former aims at vessel normalization, whereas the latter exploits
the cytokine as an inflammatory agent that induces vascular
activation.
Alternative approaches to target the VEGF-VEGF receptor
(VEGFR) pathway are immunization against VEGFR-2 (64) or
the adoptive transfer of autologous T cells genetically engineered
to express a chimeric antigen receptor targeted against VEGFR-2
[Figure 2D; (65)]. The simultaneous targeting of VEGFR-2 and
TAAs by a mixture of genetically engineered T cells expressing a
chimeric antigen receptor targeting VEGFR-2 and T cells express-
ing a TCR specific for a melanoma-associated TAA synergistically
eradicated established melanoma tumors in mice and prolonged
their tumor free survival (66). The mechanism behind this synergy
is still under investigation, and the transduction of anti-VEGFR-2
CAR into TCR transgenic T cells did not enhance the therapeutic
efficacy of adoptively transferred cells (66). Because of the exten-
sive tumor necrosis induced by the adoptive transfer of T cells,
vessels could not be investigated in these tumors (66). The authors
favor the hypothesis that anti-VEGFR-2 T cells not only target ECs
but also suppressor cell populations including MDSCs and Tregs
that express VEGFR-2 (67, 68).
In general, anti-VEGF-mediated transient normalization of
tumor vessels lasts between few days to a month (29). Unfor-
tunately, the anti-angiogenic drugs available to date are not suf-
ficiently selective in damaging only neo-angiogenic vessels. Risks
of sustained and/or aggressive anti-angiogenic therapies are the
unselected recruitment of pro-angiogenic inflammatory cells, and
excessive trimming of vessels with inadequate delivery of oxy-
gen and drugs. The latter effect may be dangerous also for highly
vascularized tissues, including the cardiovascular, endocrine, and
nervous systems (69).
As mentioned before, targeting TNF to the tumor vessels
enhances tumor permeability to chemotherapeutic agents (48). We
have recently reported that the combination of active or adoptive
immunotherapy, vascular targeting, and chemotherapy act in syn-
ergy against melanoma (49). Our preliminary results also suggest
that in the context of adoptive T cell therapy after hematopoi-
etic stem cell transplantation (70, 71), NGR-TNF dramatically
increases the infiltration of TILs into the prostate of mice affected
by autochthonous prostate cancer (49) and contributes to tumor
debulking (Mondino A. Personal communication).
Interestingly, chemotherapeutic agents, beside their effects in
promoting anti-tumor immunity by inducing a more immuno-
genic death of cancer cells, increasing their sensitivity to immune
effectors or depleting the tumor microenvironment of Treg cells
and MDSCs (72, 73) have been shown to promote intratumor
expression of chemokines attracting T cells (74).
Taken together, these findings support the concept that increas-
ing T-cell traffic to the tumor, possibly in association with
immunogenic chemotherapy, may be a valid strategy to enhance
response to immunotherapy in cancer patients.
REPROGRAMING ENERGY METABOLISM IN CANCER
Reprograming energy metabolism is an emerging hallmark of can-
cer closely linked to hypoxia and neoangiogenesis (25). Indeed,
uncontrolled cell proliferation requires a continuous adjustment
of energy metabolism in order to fuel cell growth and division
also in the absence of adequate tumor perfusion (14). As early as
in 1930, Otto Warburg showed that cancer cells craving for energy
take up much more glucose than normal cells and mainly process
it through aerobic glycolysis, the so-called “Warburg effect” (75).
Curiously enough, also T cells that differentiate from the naïve
to the effector state upregulate genes encoding glycolytic enzymes
(76), but tumor cells incorporate 10- to 100-fold greater glucose
than T cells over a fixed time period (77), thus suggesting a biased
competition for glucose between cancer cells and activated T cells
within the same microenvironment.
As summarized in Figure 3, a direct consequence of aero-
bic glycolysis is the production of lactate from pyruvate, and
acidic metabolites that cause drop in extracellular pH (78), which
may select for more aggressive acid-resistant clones and favor
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FIGURE 3 | Metabolic alterations within the tumor
microenvironment. The cartoon summarizes the metabolic alterations
often found within the tumor microenvironment that may impact on T cell
fitness. See the text for more details. ATP, Adenosine-5′-triphosphate;
HIF-1, hypoxia inducible factor 1; ROS, reactive oxygen species; TRX,
thioredoxin.
tumor invasion (14). Pyruvate decarboxylation within mitochon-
dria causes the generation and subsequent release of CO2, which
favors increased expression of carbonic anhydrase IX (CA-IX), a
cancer-associated membrane bound isoform of the enzyme car-
bonic anhydrase that catalyzes the hydration of CO2 to bicarbonate
and H+, thus contributing to acidify the extracellular microen-
vironment of tumors (79, 80). A low extracellular pH triggers
the activation on tumor cell membranes of transporters that pro-
tect the cytosol from acidosis. In addition, hypoxia stabilizes the
heterodimer HIF-1, which in turn induces the up-regulation of
glucose transporters and CA-IX, thereby increasing acidity within
the tumor microenvironment (80). As a result, while in normal
tissues the extracellular pH is maintained around 7.4, in malig-
nant tumors the pH can drop to values of 6.0 and less, with
averages of 0.2–0.6 units lower than in normal tissues (81). The
tumor-supporting role of low pH has been recently corroborated
by the observation that pharmacologic inhibition of CA-IX or of
the vacuolar H+-ATPases display antineoplastic effects (79, 82).
Hypoxia and pH are also strongly tangled with reduction-
oxidation (redox) reactions (Figure 3). Already at the earliest
stages of tumor development, free radicals, HIF-1-induced gene
expression and hypoxia are strictly interconnected (83). Indeed,
reactive oxygen species (ROS) are generated in mitochondria of
cells exposed to low oxygen (84), and the phenomenon is further
amplified by cyclic reoxygenation. Also the anti-oxidant systems
upregulated by tumor cells to counterbalance oxidative stress con-
tribute to the altered redox of the tumor microenvironment and to
tumor progression. Overexpression of reducing enzymes such as
thioredoxin (TRX) has been found in many tumors and correlated
to poor prognosis (85, 86). TRX induces and stabilizes HIF-1α
(87), and co-localizes with both HIF-1α and CA-IX in hypoxic
areas of the tumors (79). In addition, proton pumps have been
proposed to de-toxify tumor cells from microenvironmental ROS
(88). Thus, hypoxia, acidosis, redox-remodeling can cooperate to
establish a more aggressive malignant phenotype, and possibly to
promote the derangement of immune functions (77).
ALTERATIONS OF THE TUMOR METABOLISM THAT IMPACT
ON T CELL FITNESS
The immune system has been proposed as sensor of the meta-
bolic state (89). Bidirectional communication and coordination
between metabolism and immunity, while effective in maintain-
ing and defending the internal environment from the environment
around us, may result in inhibition of immune functions and may
favor chronic inflammation and cancer. A well-known example
of metabolism-mediated limitation of the function and survival
of TILs is tryptophan consumption by tumor cells and antigen
presenting cells (APCs) producing IDO (90). This mechanism
can also restrain the therapeutic efficacy of checkpoint blockade
strategies such as targeting of cytotoxic T lymphocyte antigen-
4 (CTLA-4), glucocorticoid-induced TNFR family related gene
(GITR), and the PD-1/PD-L1 axis (91).
More specifically, hypoxia, acidosis, and redox-remodeling are
all perceived as sensors by the immune system. Thus, as sum-
marized in Table 1, hypoxia inhibits TCR-triggered signaling,
proliferation and cytokine production by T cells (92, 93). Intra-
cellular HIF-1α appears to have a direct role in T cell inhibition,
since HIF-1α is induced upon TCR triggering (94, 95), it is further
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Table 1 | Effects of the tumor metabolism onTILs.
Metabolic alteration Species Inhibition Promotion Reference
Hypoxia Mus musculus Expansion of CD8+ T cells Development of more lytic CTLs Caldwell et al. (92)
IL2 and IFNγ production by CD8+ and CD4+
T cells
VEGF production
Expression of TCR and LFA-1 on
CD8+ T cells
Human Voltage-dependent K+ channels Conforti et al. (93)
Mus musculus HIF-1α expression Lukashev et al. (94)
Mus musculus Accumulation of extracellular
adenosine
Sitkovsky et al. (96)
Human and Mus
musculus
Treg recruitment Facciabene et al. (97)
Mus musculus Treg differentiation Th17 differentiation Dang et al. (98)
Human Th17 survival Kryczek et al. (100)
Mus musculus T cell-mediated cytotoxicity MacDonald (105)
Low intratumor pH Human and Mus
musculus
Lymphocyte apoptosis Lugini et al. (108),
Calcinotto et al. (113)
Mus musculus CTL response in vivo CTL activation in vitro Droge et al. (109)
Mus musculus IL2-mediated T cell proliferation Ratner (110)
Mus musculus CTL-mediated cytotoxicity Redegeld et al. (111)
Human Proliferation and effector function of T cells Fischer et al. (112)
Human and Mus
musculus
CTL proliferation, cytolitic activity and IL2,
TNFα and IFNγ production
Calcinotto et al. (49)
Oxidative stress Human and Mus
musculus





Mus musculus Activation of JAK, STAT, ERK and AKT Bingisser et al. (125),
Mazzoni et al. (126)
Mus musculus Conformational flexibility of TCR and CD8
molecules
Nagaraj et al. (134)
Human and Mus
musculus
Intratumor infiltration of T cells Molon et al. (135)
Human Release of cysteine and TRX by DCs Angelini et al. (137)
increased in hypoxic conditions, and knocking down HIF-1α in T
cells increases their cytokine production potential both in vitro
and in vivo (94). T cells are also inhibited by hypoxia-driven
accumulation of extracellular adenosine (96).
More recently it has been reported that hypoxia within the
tumor microenvironment promotes Treg recruitment through
the induction of CC-chemokine ligand 28 (97). Conversely, up-
regulation of HIF-1α under hypoxic conditions inhibits Treg
differentiation through FoxP3 degradation, and favors the differ-
entiation of Th17 cells by directly inducing RAR-related orphan
receptor gamma t (RORγt) transcription (98) and glycolytic genes
(99). HIF-1α also induces several survival promoting genes in
Th17 cells, thus preventing their apoptosis (100). Th17 cells are
a subpopulation of T helper cells producing IL17, IL17F, and IL22,
which play a critical role in immunity to certain pathogens and
autoimmune inflammation (101). The role of Th17 cells in cancer
is more debated. Indeed, Th17 exert anti-tumorigenic activities,
likely by facilitating the recruitment of other effector immune
cells (102), and pro-tumorigenic activities by inducing tumor
vascularization and the release of tumor-promoting factors by
tumor and stromal cells (103). Thus, the effects of hypoxia on the
tumor microenvironment are rather complex, and the use of HIF
inhibitors for therapeutic purposes should be carefully balanced
to avoid the dominance of pro-tumorigenic over anti-tumorigenic
mechanisms.
Hypoxia may also render the tumor cells more resistant to
cytotoxic T lymphocyte (CTL)-mediated lysis through HIF-1α-
dependent induction in cancer cells of miR-210, which downreg-
ulates the expression of PTPN1, HOXA1, and TP53I11 genes (104).
It remains to be defined how coordinated silencing of these three
genes affects cancer cell susceptibility to CTL lysis. The effect of
hypoxia on CTLs is still debated (77). Interestingly, simultaneous
glucose deprivation and hypoxia block T cell-mediated cytotoxi-
city in vitro (105), therefore suggesting an additional mechanism
of immunosuppression within the tumor microenvironment.
There are relatively few reports on the impact of low intratu-
mor pH on T cells (106). Clinical evidence suggests that metabolic
acidosis is often associated with immunodeficiency (107). Indeed,
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both leukocyte activation and the bactericidal capacity of leuko-
cytes are generally impaired at reduced pH (106) suggesting that T
cells could be extremely sensitive to pH variations. Lymphocytes
also die at the same acidic pH malignant tumor cells perfectly
remain alive (108). Droge et al. (109) studied the effect of lac-
tate on murine T-cell populations and found that lactate is able
to suppress the CTL response in vivo, whereas activation of CTLs
in vitro is increased. Few years later, it was reported that the pro-
liferation of IL-2-stimulated T cells is inhibited at pH 6.7 (110),
and the cytolytic activity against cancer cells of CTLs is markedly
reduced when T cells are exposed to acidic pH (111). More recently,
Fischer and colleagues demonstrated that high lactic acid concen-
trations, as the ones found in the tumor environment, block lactic
acid export in human T cells, thereby disturbing proliferation and
effector functions (112).
We have found that lowering the pH in vitro to values most
frequently detected within tumors (pH 6–6.5) induces hypore-
sponsiveness in both human and mouse tumor-specific CTLs,
which is characterized by impaired proliferation, cytolytic activity,
and cytokine secretion (113). Interestingly, buffering of culture
pH to physiologic values associates with the complete recovery
of T cell functions, although longer exposure or lower pH val-
ues causes permanent damage and T cell death (113), arguing
that a portion of T cell immunity might be lost at tumor site
when extreme metabolic alterations are present. From a molecu-
lar standpoint, TCR triggering at low pH associates with reduced
expression of IL-2Rα (CD25) and TCR, and diminished activa-
tion of signal transducer and activator of transcription 5 (STAT5)
and extracellular signal-regulated kinase (ERK) (113), signaling
alterations frequently found in anergic T cells (114, 115). Inter-
estingly, similar characteristics were found in tumor-specific CTLs
infiltrating melanoma lesions, whose pH was 6.5 (113). Thus, acid-
ity per se is a novel tumor cell extrinsic mechanism of immune
escape (116).
Whereas redox-activated signaling events are physiologically
needed both as antimicrobial defense and to guarantee the cor-
rect spatial and temporal extension of the immune reaction,
redox-remodeling within the tumor microenvironment negatively
affects immune surveillance. Indeed, oxygen ions and perox-
ides are potent antibacterial agents produced by phagocytic cells
including macrophages and neutrophils (117). ROS are also impli-
cated in NLRP3 inflammasome activation in myeloid cells (118).
It has also been increasingly appreciated that endogenous ROS
are required for optimal T cell activation (119). Yet, exogenous
oxidative stress may dramatically suppress T cell activation and
effector functions. As an example, macrophages within the tumor
microenvironment express inducible nitric oxide synthase (iNOS)
and can induce tumor killing by generating large amounts of nitric
oxide (NO). However, iNOS is also expressed by MDSCs, a het-
erogeneous population of cells of myeloid origin that include
immature macrophages, granulocytes, DCs and other myeloid
cells (57). MDSCs also express arginase 1 (Arg1) that together with
iNOS metabolizes the essential aminoacid arginine to either l-
ornithine and urea, or to l-citrulline and NO (120, 121). Depletion
of arginine from the microenvironment induces T cell dysfunction
because of loss of CD3ζ chain expression (122, 123), and prevents
the up-regulation of cell cycle regulators by these cells (124), thus
blocking their proliferation. In addition, NO blocks the activation
of Janus-activated kinase 1 (JAK1), JAK3, STAT5, ERK, and AKT
(125, 126), thus suppressing several T cell functions (125–129).
Depletion of l-arginine may also trigger superoxide (O−2 ) gen-
eration from iNOS (130, 131), which is eventually converted to
hydrogen peroxide. ROS contribute to the MDSC-mediated sup-
pression of tumor-specific T cell responses in tumor-bearing mice
(57, 132).
Finally, the reaction between NO and O−2 generates reac-
tive nitrogen-oxide species (RNOS), among which peroxynitrite
(ONOO−) (133). ONOO−mediated nitration of tyrosine residues
in the TCR and CD8 co-receptor causes a decreased conforma-
tional flexibility of these molecules and failure in proper T cell acti-
vation (134). Nitration of chemokines also prevents intratumoral
infiltration of antigen-specific T cells (135).
Also Tregs modulate the redox of the microenvironment by
subtracting cysteine necessary to effector T cell, function (136).
Indeed, DCs within the tumor microenvironment may have addi-
tional nutritional and redox-remodeling roles, since they reduce
the extracellular microenvironment required for T cell activa-
tion by releasing cysteine and TRX (137). In the same vein, Tregs
diminish glutathione synthesis in DCs and consume extracellular
cysteine (138), thus remodeling extracellular redox.
Additional hypoxia-driven metabolic dysfunctions, leading to
the accumulation of extracellular adenosine, further increased by
Tregs (139, 140), could act in synergy with acidic pH in dampen-
ing T cell function through A2A adenosine receptor-driven cAMP
intracellular accumulation (96).
All together these findings sustain the concept that hypoxia,
nutrient deprivation, abnormal glycolysis, and low pH act in
synergy crippling immune surveillance (Figure 1).
Also alterations of the lipid metabolism that occur in the tumor
microenvironment might affect T cell functions [e.g., (141)], but
direct in vivo evidences of this phenomenon are poor.
STRATEGIES THAT IMPACT ON TUMOR METABOLISM AND
PROMOTE FITNESS OF TUMOR INFILTRATING LYMPHOCYTES
Different therapeutic approaches have been proposed to mod-
ulate hypoxia, tumor acidity or redox, which directly or indi-
rectly affect TIL viability and effector functions (Figure 1).
Being the tumor microenvironment so complex and redundant,
the risk remains that interfering with one metabolic pathway,
thus inhibiting one pro-tumoral mechanism, may favor another.
For the sake of brevity, we will touch upon some clarifying
examples.
It has been reported that the anti-VEGF monoclonal antibody
bevacizumab induces intratumoral hypoxia, likely through exces-
sive vessel remodeling (142), thus increasing the population of
cancer stem cells (CSCs) in human breast cancer xenografts (143),
and promoting epithelial to mesenchymal transition (EMT) in a
murine model of bevacizumab-resistant pancreatic cancer (144).
Angiogenesis inhibitors targeting the VEGF pathway may also
elicit tumor adaptation and progression to stages of greater malig-
nancy, with heightened invasiveness and in some cases increased
lymphatic and distant metastasis (145). Bevacizumab has also
been shown to induce malignant traits through induction of
paracrine factors, which recruited pro-angiogenic myeloid cells
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(146), whose phenotype is reminiscent of MDSCs. Thus, anti-
angiogenic compounds while cutting nutritional support to tumor
cells, may favor local hypoxia and MDSC accumulation.
Also sunitinib, a receptor tyrosine kinase inhibitor with anti-
angiogenic properties (147), which has been recently approved for
the treatment of metastatic renal cell carcinoma (148), induces
hypoxia, through a yet undefined mechanism, and increase in
CSCs (143). Interestingly, semaphoring 3A (Sema3A), an endoge-
nous anti-angiogenic agent, counteracts sunitinib-induced tumor
hypoxia, and Sema3A and sunitinib synergize to enhance survival
of tumor-bearing mice (149). In addition, one cycle of treatment
with sunitinib is sufficient to increase the proportion of type 1
T cells (150), likely by reducing MDSCs (151). These findings
have been confirmed in mouse models of cancer, in which suni-
tinib reduced viability and proliferation of MDSCs (152) and their
accumulation in tumors (153).
Several drugs have been identified that target HIF-1α, thus
inhibiting angiogenesis (154). However, HIF-1 inhibitors may
impact on balance between Treg and Th17 cells favoring the former
(99, 155). Thus, further investigation is needed to fully elucidate
the therapeutic potential of HIF-1 inhibitors in cancer patients.
Conversely, hypoxia can be skillfully utilized to selectively
target TILs. Indeed, hypoxia induces expression of CD137 (4-
1BB) on TILs, and low-dose intratumoral injections of agonist
anti-CD137 monoclonal antibodies avoid systemic toxicity while
achieving anti-tumor systemic effects (156). In addition, intratu-
moral anti-CD137 antibodies synergized with systemic blockade
of PD-L1 (156).
Several strategies have been proposed to neutralize intratumor
acidity and therefore affect TILs. Robey et al. (157) reported that
oral treatment with NaHCO3 increased the extracellular pH of
spontaneous metastases, inhibited cancer cell extravasation and
colonization in mouse models of breast and prostate cancer. How-
ever, no information is available on the effects of systemic adminis-
tration of bicarbonate on T cells and there is some concern related
to the risk of metabolic alkalosis.
We obtained evidence that systemic administration of the PPI
esomeprazole (12.5 mg/Kg) to tumor-bearing mice caused a rapid
(within 60 min) increase in tumor pH, which associated with
enhanced IFNγ production by TILs (113). Indeed, on a per cell
basis, TILs in the tumor of PPI-treated mice produced more IFNγ
than TILs from mice treated with vehicle (113). PPI treatment
also increased phosphorylated ERK in TILs, thus giving molecular
support to the PPI-mediated effect. As expected for a drug that is
administered as a pro-drug and requires protonation at low pH
(158), IFNγ production by T cells isolated from the spleen, lung,
and kidney of mice treated either with PPIs or vehicle did not dif-
fer (113), thus suggesting that also the effects of PPIs on T cells are
restricted to area of acidosis. PPIs also affected adoptively trans-
ferred T cells that reached the tumor, and PPI treatment increased
the therapeutic potential of both active and adoptive immunother-
apies (113). Because of the high selectivity for an acidic milieu and
instability, PPIs can be safely used at high doses (158) as the one
tested by us (113), which also affect tumor cells in vivo (159).
Thus, PPI treatment may represent a promising strategy for recov-
ering specific immunity and improving the efficacy of T cell-based
cancer treatments.
PPIs are also known for their anti-oxidant and anti-
inflammatory activities (160). Vacuolar proton pumps are
expressed in the membrane of phagolysosomes of neutrophils, and
lysosomal acidification is relevant for neutrophil oxidative burst.
Thus, PPIs reduce release of ROS by neutrophils further impact-
ing on the tumor microenvironment. Whiles the mechanism of
action of PPIs on leukocytes is still under investigation (160), our
data suggest that in vivo PPIs enhance anti-tumor activities of TILs
(113, 116).
Cancer cells promote chronic autophagy as survival adaptation
to the acidic microenvironment (161). Because at least in vitro
autophagy can also be induced in tumor cells by PPIs (162),
strategies might be devised to inhibit autophagy during PPI treat-
ment, yet taking into account the potentially negative effects of
autophagy inhibitors on TILs (163).
Regarding redox, it has been reported that the anti-diabetic
drug metformin or the mTOR inhibitor rapamycin, restore cata-
bolic mitochondrial fatty acid oxidation and favor the induction of
memory T cells, thus increasing the therapeutic efficacy of cancer
vaccines (141, 164, 165).
Several pre-clinical studies also support the use of A2A adeno-
sine receptors (A2ARs) antagonists to increase T cell activity within
the tumor microenvironment (166). As an example, the com-
pounds ZM241385 or 1,3,7-trimethylxanthine (caffeine) showed
to increase the anti-tumor activity of adoptively transferred T cells
in mice bearing large tumors (167). Curiously, drinking coffee was
found to correlate with significant decreased risk of cutaneous
malignant melanoma only in women (167, 168), suggesting that
caffeine may also impact on cancer immune surveillance.
Finally, therapeutic strategies targeting either Tregs (169, 170)
or MDSCs (171, 172); (173, 174), collaborate in making the tumor
microenvironment more permissive for TIL survival and anti-
tumor activities. Interestingly, MDSCs impair T cell trafficking
through down-regulation of CD62L on CD4 and CD8 T cells
(175) and chemokine nitration (135). Thus, therapeutic strategies
that block MDSCs accrual at the tumor site and their immuno-
suppressive function, and more specifically drugs interfering with
chemokine nitration, are expected to significantly improve the
efficacy of both active and adoptive immunotherapies.
CONCLUSION AND PERSPECTIVES
Despite considerable progress over the last decade, the tumor
microenvironment is an area of research that remains ripe
for further investigation, especially with regard to the relent-
less and dynamic modifications in its cellular composition and
metabolism.
Accumulating experimental evidence lends weight to the con-
cept that the most effective therapeutic strategies against cancer
will be the ones that consider the tumor and its microenviron-
ment as a whole, and yet simultaneously and coordinately address
several individual aspects of this complex system. So far, either
chemotherapy, surgery or radiotherapy have been combined with
either one of active immunotherapy and/or adoptive T cell therapy,
checkpoint blockade strategies or drugs that modify the vascu-
larization and metabolism of the tumor (38, 50, 116, 176–178),
thus improving distribution and synergistic anti-cancer activity
of drugs and T cells. A step forward will be to carefully devise
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multiple targeted therapies that simultaneously or subsequently
attack tumor cells and the diverse aspects of the tumor microen-
vironment, and yet preserve the function of organs not involved
by the neoplasm. Thus, it can be anticipated that adoptive and
active immunotherapy given together with treatments that tran-
siently normalize and/or activate tumor-associated ECs and drugs
that impact on tumor metabolism and reduce the local immuno-
suppressive environment would greatly benefit cancer patients
without causing relevant systemic toxic effects. As an example, in
TRAMP mice affected by advanced prostate cancer, the combina-
tion of non-myeloablative total body irradiation, hematopoietic
stem cell transplantation, infusion of donor mature lympho-
cytes, and tumor-specific vaccination overcomes tumor-specific
T cell tolerance, prompts tumor debulking, and induces long-
lasting tumor-specific memory response that protects mice from
tumor recurrence (70). Interestingly, the addition of NGR-TNF
at the peak of the vaccination-induced immune response favors
penetration of activated T cells within the transformed prostate
epithelium (49) and guarantees an even stronger anti-tumor activ-
ity (Mondino A. Personal communication). We are investigating
the possibility to add PPIs to this already complex combined ther-
apy to favor the anti-tumor activity of adoptively transferred and
vaccine-induced T cells that have reached the prostate.
Given the outstanding results obtained with immune check-
point blockers in cancer patients (179), it will be particularly inter-
esting to investigate the therapeutic efficacy of their combination
with metabolism and vessel modulators.
It is also important to underline that more is not always bet-
ter (180). One example is the recent failure of a well-designed
and carefully analyzed multi-institutional clinical trial in which
732 patients with previously untreated metastatic colorectal
cancer were randomly assigned to receive the combination of
capecitabine, oxaliplatin, and bevacizumab (i.e., a monoclonal
antibody against VEGF) or the same three drugs with cetuximab
(i.e., a monoclonal antibody directed against the epidermal growth
factor receptor; EGFR) (181). The four-drug combination resulted
in significantly shorter progression-free survival and inferior qual-
ity of life. A similarly negative effect was obtained when another
anti-EGFR monoclonal antibody (i.e., panitumumab) was added
to the combination of folinic acid, fluorouracil, oxaliplatin, and
bevacizumab in previously untreated metastatic colorectal cancer
patients (182).
Thus, additional investigation is needed to define the best set-
tings for each combination approach. In this perspective, reliable
animal models of human diseases remain instrumental.
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